SCHEMBL3017556

SCHEMBL3017556

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4c(F)cccc4F)CC3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.59
SMN1; SMN2 Q16637 7/20 0.58
RAB9A P51151 5/20 0.58
NPC1 O15118 3/20 0.55
ALDH1A1 P00352 8/20 0.55
MAPK1 P28482 7/20 0.52
LMNA P02545 6/20 0.52
USP2 O75604 3/20 0.49
HSD17B10 Q99714 2/20 0.49
RECQL P46063 1/20 0.49
TP53 P04637 3/20 0.48
HTT P42858 2/20 0.48
ALOX15 P16050 1/20 0.48
AR P10275 2/20 0.48
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
TSHR P16473 1/20 0.45
GAA P10253 1/20 0.45
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008347 0.91 MAPT (0.53) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3015653 0.90 MAPT (0.61) MAPTSMN1; SMN2ALDH1A1MAPK1LMNA
SCHEMBL3006478 0.90 SMN1; SMN2 (0.60) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3010922 0.90 MAPT (0.47) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3014809 0.89 SMN1; SMN2 (0.56) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3014671 0.88 LMNA (0.55) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3015540 0.88 SMN1; SMN2 (0.57) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3012406 0.87 MAPT (0.53) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3005407 0.86 MAPK1 (0.49) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3015056 0.86 REV1 (0.52) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.